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Abstract: Alteration of the phosphatidylinositol 3-kinase (PI3K)/AKT/mammalian target 
of rapamycin signaling pathway is key for the growth and survival of several cancers, includ-
ing breast cancer. In addition, dysregulation of PI3K signaling may contribute to resistance 
to several anticancer agents. PI3K inhibitors may, therefore, be effective as antineoplastic 
therapy. Buparlisib is a potent and highly specific oral inhibitor of the pan-class I PI3K family. 
Buparlisib specifically inhibits class I PIK3 in the PI3K/AKT kinase signaling pathway in an 
ATP-competitive manner, thus inhibiting the production of the secondary messenger phosphati-
dylinositol (3,4,5)-trisphosphate and activation of the PI3K signaling pathway. This may induce 
inhibition of tumor cell growth and survival in susceptible tumor cell populations. Buparlisib 
is currently under investigation in patients with a variety of solid tumors, including breast 
cancer. Buparlisib has been validated as a promising anticancer agent, and tremendous efforts 
have been taken to develop it. However, buparlisib monotherapy has resulted in humble benefit 
so far. Results from studies combining buparlisib with different anticancer agents – namely, 
endocrine therapy, anti-HER2 therapy, and chemotherapy – have showed variable efficacy with 
consistent substantial toxicity.
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Introduction
Phosphoinositide 3-kinase (PI3K) pathway, a critical signal transduction system which 
links oncogenes and several receptor classes to different key cellular functions, is one 
of the most widely activated signaling pathways in cancer.1
The family of lipid kinases called phosphoinositide 3-kinases (PI3Ks) plays essen-
tial regulatory roles in different cellular processes including cell survival, proliferation, 
differentiation, cytoskeletal organization, and glucose transport.2–4
There are three classes of PI3Ks which differ in their structural characteristics 
and substrate specificity.5,6 Class I enzymes are the most commonly studied; they are 
activated directly by cell surface receptors. Furthermore, class I PI3Ks are divided into 
class IA enzymes, which are activated by RTKs, GPCRs, and some oncogenes such as 
the small G protein Ras, and class IB enzymes, which are regulated only by GPCRs.
These enzymes – through the formation of the second messenger phosphatidylino-
sitol (3,4,5)-trisphosphate – activate many target proteins, most notably phosphoinosit-
ide-dependent kinase-1. The downstream targets of these protein kinases, such as 
mammalian target of rapamycin (mTOR), BCL2-associated agonist of cell death, and 
forkhead box O proteins, regulate proliferation, growth, and survival.7
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Alteration of the PI3K/AKT/mTOR pathway is key for 
the growth and survival of several cancers, including breast 
cancer (BC). Different aberrations in the PI3K signaling 
pathway, such as PI3K mutation/amplif ication, loss/
mutation of the phosphatase and tensin homologue, AKT 
overexpression/overactivation, and modulation of tuberous 
sclerosis protein 1 and 2 tumor suppressors, may be often 
observed in BC, predominantly in hormone receptor-positive 
(HR+) tumors.8 Especially, as PI3K is the most proximal 
component of the pathway, targeting PI3K itself rather than 
AKT or mTOR with PI3K inhibitors may induce pronounced 
inhibition of the downstream components within the pathway. 
Many inhibitors of mTOR have been developed for the 
treatment of cancers, mostly analogs of rapamycin, which 
specifically inhibit the activity of the TORC1 complex.9 
However, specific inhibition of TORC1 results in a feedback 
stimulation of AKT, thus providing an inferior therapeutic 
efficacy compared to inhibition of PI3K and both TORC 
complexes.10 Moreover, activation of PI3K pathway may be 
associated with resistance to a variety of antitumor agents.11–13
Targeting PI3K pathway
HR+ tumor is the most frequent subtype of BC, with 
endocrine therapy (ET)-based regimens being its backbone 
of treatment.14,15 However, HR+ BC is not homogeneous, but 
characterized by different genomic alterations that on one 
hand may affect treatment outcomes and on the other hand 
may offer many therapeutic opportunities with the use of 
targeted agents.14,16 Of particular interest, activating PIK3CA 
mutations (which encode the p110α isoform of PI3K) are 
frequently detected in HR+ BC and are possibly associated 
with disease progression and resistance to ET.14,17–19
Roughly, 40% of human epidermal growth factor receptor 
2-positive (HER2+) BCs harbor activating mutations in 
PIK3CA.14 These two oncogenes have different functions 
and may work together to stimulate tumor growth. Several 
anti-HER2 agents are approved for the treatment of patients 
with HER2-positive BC. Nonetheless, both de novo and 
acquired resistance to anti-HER2 therapies may occur.20 
PIK3CA mutations might be implicated in conferring 
resistance to these therapies.21–23 Given that PIK3CA-mutant 
BC appears to have distinct tumor biology, development of 
more individualized targeted therapies based on the PIK3CA 
genotype is awaited.
Therefore, targeting PI3K may be a valid therapeutic 
option in these settings. In order to maximize treatment 
efficacy, it would be crucial to identify those patients with 
PIK3CA mutations who might derive the greatest benefit 
from PI3K inhibitors.
Several clinical studies have been conducted – mainly in 
the setting of HR+/HER2− metastatic disease – to explore 
the combination of endocrine therapies with agents targeting 
PI3K/Akt/mTOR, such as PI3K inhibitors (panspecific or 
specific to the subunit 110 α or δ), AKT inhibitors, mTOR 
inhibitors, or dual inhibitors of mTOR and PI3K. Among 
these drugs, everolimus is the only PI3K inhibitor approved in 
combination with exemestane for the treatment of postmeno-
pausal patients with endocrine-resistant HR+/HER2− BC.24 
An exploratory analysis of the BOLERO-2 study showed that 
the benefit of adding everolimus to ET was consistent regard-
less of PIK3CA alteration.25 AZD2014 is a promising dual 
inhibitor of mTORC1 (rapamycin sensitive) and mTORC2 
(rapamycin insensitive), which is currently under investiga-
tion in a randomized Phase II trial (MANTA).26 Temsirolimus 
was tested in the Horizon study in combination with letrozole, 
but no benefit in terms of progression-free survival (PFS) 
was observed compared to letrozole alone.27 The FERGI 
trial assessed the combination of pictilisib (GDC-0941), 
an oral inhibitor of multiple class I PI3K kinase isoforms, 
and fulvestrant.28 This study demonstrated a nonsignificant 
benefit in terms of PFS in the pictilisib arm compared with 
the placebo arm (6.2 vs 3.8 months; hazard ratio, 0.77; 95% 
CI, 0.50–1.19), independent of PIK3CA mutation status.28 
Alternative strategies include specific inhibition of subunit 
α PI3K (alpelisib) or mutated PI3K (taselisib); initial results 
from the LORELEI study were presented at European Society 
for Medical Oncology 2017 and showed a benefit in terms 
of objective response rate for the addition of taselisib to 
neoadjuvant letrozole in postmenopausal patients with HR+/
HER2− early BC.
Buparlisib is a potent and highly specific oral pan-class 
I PI3K inhibitor, which is currently under investigation in 
patients with a variety of solid tumors, including BC. In this 
article, we focus on the main characteristics of buparlisib and 
its potential application in the treatment of BC.
Buparlisib has demonstrated preliminary activity in 
preclinical models, providing a rationale for its use in 
clinical practice.29 Preclinical data showed that this drug, 
at high concentrations, might cause cell death in various 
cellular systems, irrespective of the level of PI3K addiction. 
Moreover, this agent may interfere with microtubule 
assembling, inducing cell cycle arrest at G2–M phase. 
However, at doses and schedules used in clinical settings, 
these effects may not occur.30
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In early-phase clinical studies, buparlisib showed encour-
aging tolerability profile, but modest clinical efficacy as a 
single agent.31 As the PI3K pathway is involved in resistance 
to anticancer treatments, a more promising therapeutic 
strategy likely consists in combining buparlisib, and PI3K 
inhibitors in general, with other agents in order to restore 
sensitivity to such treatments.32–35 Different trials testing the 
combination of this PI3K inhibitor with various anticancer 
drugs are ongoing and are summarized in Table 1.
Materials and methods
We searched PubMed for articles published anytime until 
September 23, 2017, using the terms “buparlisib” AND 
“breast cancer”, and identified 45 full-text articles in 
English. Of these articles, 10 publications were reviews. 
Five publications reported original data from Phase I 
clinical trials involving buparlisib in BC, and one publi-
cation related to Phase III trial of buparlisib in BC was 
identified.
Table 1 Ongoing trials testing the combination of buparlisib with various anti-cancer drugs
Subtype Setting #NCT Phase Status Number of  
patients
Treatment
HR+
HER2−
Locally advanced/metastatic BC 
previously treated with AI and 
mTOR inhibitors
NCT01633060 
(BELLE-3)
III ANR 432 BMK120/placebo + fulvestrant
Locally advanced/metastatic BC 
refractory to AI
NCT01610284 III ANR 1149 BMK120/placebo + fulvestrant
Locally advanced/metastatic BC 
with prior hormonal therapy
NCT02404844
PIKTAM
II ANR 48 BMK120 + tamoxifen
Neoadjuvant treatment of EBC NCT01923168 II C 340 BYL719/placebo + letrozole
BMK120/placebo + letrozole
Metastatic BC NCT02088684 Ib/II ANR 70 LEE011 + BKM120 + fulvestrant
LEE011 + BYL719 + fulvestrant
LEE011 + fulvestrant
Locally advanced/metastatic BC NCT02058381 
(B-YOND)
Ib ANR 40 BYL719 or BKM120 + tamoxifen + 
goserelin acetate
Metastatic BC NCT01339442 I C 31 BMK120 continuous or intermittent + 
fulvestrant
HR+
HER2+/−
Metastatic BC NCT01248494 Ib C 72 BEZ235 + letrozole
BKM120 continuous + letrozole
BMK102 intermittent + letrozole
HR+/HR−
HER2+
Neoadjuvant treatment in EBC NCT01816594 
(NeoPHOEBE)
II C 50 BKM120/placebo + trastuzumab + 
paclitaxel
HR+/HR−
HER2−
Locally advanced/metastatic BC NCT01572727
BELLE-4
II/III C 416 BMK120/placebo + paclitaxel
HR+/−
HER2+/−
Metastatic BC NCT01300962 I ANR 47 BKM120 + capecitabine
BYL719 + capecitabine
BKM120 + capecitabine + trastuzumab
BKM120 + capecitabine + lapatinib
All subtypes Metastatic BC with brain 
metastases
NCT02000882 II R 40 BKM120 + capecitabine ± trastuzumab
TNBC Metastatic BC NCT01629615 II C 50 BMK120
TNBC Metastatic BC NCT01790932 II ANR 110 BMK120
TNBC
Ovarian cancer
Metastatic BC NCT01623349 I ANR 118 BYL719 + olaparib
BMK102 + olaparib
Solid tumors Advanced solid tumors NCT01363232 Ib ANR 89 BKM120 + MEK162
Solid tumors Advanced solid tumors NCT01155453 Ib C 113 BKM120 + GSK1120212
Solid tumors
HER2+ BC
Advanced solid tumors NCT01285466 Ib C 110 BEZ235 + paclitaxel
BKM120 + paclitaxel
BEZ235 + paclitaxel + trastuzumab
BKM120 + paclitaxel + trastuzumab
Solid tumors Advanced solid tumors NCT01576666 Ib C 120 LDE225 + BKM120
Abbreviations: AI, aromatase inhibitors; ANR, active, not recruiting; BC, breast cancer; C, completed; EBC, early breast cancer; HER2, human epidermal growth factor 
receptor 2; HR, hormone receptor; mTOR, mammalian target of rapamycin; R, recruiting; TNBC, triple-negative breast cancer.
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HR+/HER2– BC
The combination of a PI3K inhibitor and endocrine treatment 
was tested in a Phase IB study of buparlisib plus letrozole 
in patients with HR+/HER2− metastatic BC whose disease 
was refractory to ET.36 In this study, 46 patients were 
evaluable for response and 1 achieved complete response, 1 
partial response, and 25 patients had stable disease. Clinical 
activity did not correlate with PIK3CA mutational status, 
thus suggesting that other alterations in the pathway might 
be responsible for PI3K pathway dependence.36
In the Phase III randomized, double-blind, placebo- 
controlled, multicenter BELLE-2 study, postmenopausal 
patients with HR+/HER2− metastatic BC, who had pro-
gressed on/after aromatase inhibitor therapy, were random-
ized 1:1 to receive either buparlisib (100 mg/day) or placebo, 
starting on day 15 of cycle 1, plus fulvestrant (500 mg) on 
days 1 and 15 of cycle 1, and thereafter on day 1 of 28-day 
cycles.37
PI3K pathway activation status (activated vs non-activated 
vs and unknown) and visceral disease status (present vs 
absent) were stratification factors. The objective of the trial 
was to assess the predictive value of single PI3K–AKT–
mTOR pathway alterations on the clinical response of 
buparlisib. The primary endpoints were PFS in the overall 
population, in patients with known (either activated or non-
activated) PI3K pathway status, and in patients with PI3K 
pathway activation.37
One thousand one hundred forty-seven patients were 
included in this trial; 576 received buparlisib plus fulves-
trant and 571 received placebo plus fulvestrant.37 Median 
PFS was 6.9 vs 5.0 months in the overall population, receiv-
ing either buparlisib or placebo, respectively (p=0.00021). 
Patients with known PI3K status had a median PFS of 6.8 
months when treated with buparlisib and 4.5 months with 
placebo (p=0.0033). In patients with PI3K pathway activa-
tion, median PFS was 6.8 vs 4.0 months in the buparlisib and 
placebo groups, respectively (p=0.014). Patients receiving 
buparlisib experienced more frequently grade 3–4 increased 
alanine aminotransferase (25% vs 1%), increased aspartate 
aminotransferase (18% vs 3%), hyperglycemia (15% vs 
<1%), and rash (8% vs none).37 Twenty-three percent of 
patients treated with buparlisib had serious adverse events 
as compared to 16% of patients who received placebo. 
Finally, this study showed that PI3K inhibition combined 
with ET is effective in patients with HR+/HER2− metastatic 
BC, but the toxicity associated with this combination is not 
negligible.37
PI3K pathway activation in preclinical models of BC is 
associated with tumor growth and resistance to anticancer 
therapies, including paclitaxel. Furthermore, buparlisib has 
shown synergistic activity when combined with paclitaxel in 
preclinical and clinical models. Therefore, the double-blind, 
placebo-controlled, adaptive Phase II/III BELLE-4 trial ran-
domized (1:1) patients with untreated metastatic HER2− BC 
to receive either buparlisib or placebo with paclitaxel.38 PI3K 
pathway activation and HR status were the stratification fac-
tors. The primary endpoint was PFS in the overall and PI3K 
pathway-activated populations. An adaptive interim analysis 
following the Phase II part of the study was planned to decide 
whether to go or not to Phase III (in the overall or PI3K 
pathway-activated population).38 Four hundred sixteen patients 
were entered in the trial. At adaptive interim analysis, PFS did 
not increase with buparlisib over placebo, either in the overall 
or in the PI3K pathway-activated population. Therefore, the 
study was stopped for futility.38
HER2+ BC
The PI3K/AKT/mTOR pathway is often activated in HER2+ 
BC.39 The Phase III BOLERO-1 trial combined trastuzumab 
and paclitaxel with or without everolimus in this setting and 
showed no benefit in terms of PFS in the overall population. 
Nevertheless, in the subgroup of patients with HR−/HER2+, 
there was an improvement – although not statistically 
significant – in median PFS of 7.2 months.40 Moreover, in 
the Phase III BOLERO-3 trial, addition of everolimus to 
trastuzumab and vinorelbine led to an increased median PFS 
(from 5.78 to 7.00 months) in women with HER2+ metastatic 
BC.41 A combined analysis of BOLERO-1 and BOLERO-3 
demonstrated a strong positive correlation between PI3K 
pathway activation and PFS increase.42 These findings pushed 
the investigation of PI3K inhibitors in HER+ BC.
In the CLEOPATRA study, which assessed the 
combination of pertuzumab, trastuzumab, and docetaxel 
in first-line setting,43 PIK3CA mutation was established as 
a negative prognostic factor in HER2+ BC.44 Patients with 
PIK3CA mutant tumors had a significantly worse PFS than 
those with PIK3CA non-mutant tumors.44
A Phase IB/II study has investigated the combination of 
buparlisib and trastuzumab in HER2+ BC, who previously 
progressed on trastuzumab.45 In this study, buparlisib and 
trastuzumab combination was well tolerated, with preliminary 
signs of clinical activity.45
The Phase II NeoPHOEBE neoadjuvant study was designed 
to evaluate the combination of buparlisib with trastuzumab 
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and paclitaxel in HER2+ BC in two independent cohorts 
by PIK3CA mutation status; furthermore, each cohort was 
stratified by HR status.46 The main objective of the trial was to 
assess whether PIK3CA mutation status may predict a benefit 
from combining anti-HER2 therapy and a PI3K inhibitor.46 
The trial was designed to enroll 256 patients. However, after 
enrollment of the first 50 patients, recruitment was stopped due 
to liver toxicity.46 A trend toward higher objective response rate 
(68.8% vs 33.3%; p=0.053) and a significant decrease in Ki67 
(75% vs 26.7%; p=0.021) was observed with buparlisib vs 
placebo in the HR+ subgroup.46 Unfortunately, such a treatment 
strategy does not appear to be feasible.
Buparlisib has also been studied in combination with 
lapatinib in a Phase IB/II trial including patients with 
HER2+, trastuzumab-resistant, metastatic BC.47 In the Phase 
IB part, the PI3K pathway activation status was assessed in 
a retrospective exploratory analysis, and evidence of PI3K 
pathway activation was an inclusion criterion for Phase II. 
Twenty-four patients were treated at five dose levels. Main 
drug-related adverse events included diarrhea, nausea, 
skin rash, asthenia, depression, anxiety, and increase in 
transaminases. Disease control rate was 79% (one patient 
with complete response and six patients with stable disease 
for ≥24 weeks).47 Finally, this trial showed preliminary 
evidence of antitumor activity in this heavily pretreated 
population with manageable safety profile.
Discussion
The PI3K pathway represents both an opportunity and a 
challenge for cancer treatment. In this review, we have high-
lighted both major issues and recent progress made in the 
understanding of the PI3K pathway. We have analyzed both 
the challenges and promises for the therapeutic development 
of PI3K pathway inhibitors in BC.
PI3K inhibitors have been validated as promising 
anticancer targets, and tremendous efforts have been made to 
develop this class of agents for cancer therapy. However, results 
of these drugs used as monotherapy have been modest thus far.
Overall, results from studies combining PI3K inhibition 
with different anticancer agents – although with inconsistent 
efficacy – showed consistent substantial toxicity; hence, no 
further studies are being pursued.
A potential role for PI3K-targeted therapy may warrant 
further investigation with better-tolerated second-generation 
PI3K inhibitors.
Several controversies remain regarding the best treat-
ment strategy for PI3K inhibition between pan-PI3K and 
 isoform-selective inhibitors. Different agents/class of 
agents may be more active in tumors with defined molecular 
characteristics.
Further research is needed to assess biomarkers predictive 
of response to PI3K inhibitor treatment. No correlation 
between PI3K/AKT/mTOR pathway aberrations and clinical 
response has been found to date.
Finally, the potential mechanisms of PI3K inhibitor 
resistance are still unknown and the complexity of PI3K/
AKT/mTOR pathway with extensive crosstalk with other 
signaling provides general possibility to overcome Pi3K 
inhibition. A deeper understanding of resistance mechanisms 
will enable rational design of combination regimens.
With the recent knowledge regarding the divergent roles of 
PI3K isoforms in different types of cancer, isoform-selective 
PI3K inhibitors have attracted increasing interest for precise 
cancer therapy, and over a dozen inhibitors are undergoing 
clinical evaluation (Table 1). Among them, CAL101 has 
been approved by the US Food and Drug Administration for 
patients with relapsed chronic lymphocytic leukemia and 
indolent lymphoma.
Interestingly, the PI3K pathway may be considered – at 
the same time – a dramatic therapeutic opportunity and 
a big challenge for cancer therapy with no doubt. Drugs 
targeting PI3K (or AKT or mTOR) are under investigation 
at different stages; there are potential issues associated with 
their toxicity and resistance. Oncogenic changes in PI3K 
pathway components may render cancer cells resistant to PI3K 
inhibition. Hence, it is important to identify new therapeutic 
targets for the development of agents that may either replace 
PI3K inhibitors or enhance the efficacy of PI3K inhibitors.
Further investigation is required to determine the best 
setting and the best combinations.
Disclosure
The authors report no conflicts of interest in this work.
References
 1. Liu P, Cheng H, Roberts TM, Zhao JJ. Targeting the phosphoinositide 
3-kinase pathway in cancer. Nat Rev Drug Discov. 2009;8(8):627–644.
 2. Engelman JA, Luo J, Cantley LC. The evolution of phosphatidylinositol 
3-kinases as regulators of growth and metabolism. Nat Rev Genet. 
2006;7(8):606–619.
 3. Bader AG, Kang S, Zhao L, Vogt PK. Oncogenic PI3K deregulates 
transcription and translation. Nat Rev Cancer. 2005;5(12):921–929.
 4. Vivanco I, Sawyers CL. The phosphatidylinositol 3-Kinase AKT 
pathway in human cancer. Nat Rev Cancer. 2002;2(7):489–501.
 5. Fruman DA, Meyers RE, Cantley LC. Phosphoinositide kinases. Annu 
Rev Biochem. 1998;67:481–507.
 6. Katso R, Okkenhaug K, Ahmadi K, White S, Timms J, Waterfield 
MD. Cellular function of phosphoinositide 3-kinases: implications 
for development, homeostasis, and cancer. Annu Rev Cell Dev Biol. 
2001;17:615–675.
Breast Cancer - Targets and Therapy 2018:10submit your manuscript | www.dovepress.com
Dovepress 
Dovepress
28
Criscitiello et al
 7. Carnero A, Blanco-Aparicio C, Renner O, Link W, Leal JF. The PTEN/
PI3K/AKT signalling pathway in cancer, therapeutic implications. Curr 
Cancer Drug Targets. 2008;8(3):187–198.
 8. Engelman JA. Targeting PI3K signalling in cancer: opportunities, 
challenges and limitations. Nat Rev Cancer. 2009;9(8):550–562.
 9. Chan S. Targeting the mammalian target of rapamycin (mTOR): a new 
approach to treating cancer. Br J Cancer. 2004;91(8):1420–1424.
10. Sarbassov DD, Guertin DA, Ali SM, Sabatini DM. Phosphorylation 
and regulation of Akt/PKB by the rictor-mTOR complex. Science. 
2005;307(5712):1098–1101.
11. Fekete M, Santiskulvong C, Eng C, Dorigo O. Effect of PI3K/Akt 
pathway inhibition-mediated G1 arrest on chemosensitization in ovarian 
cancer cells. Anticancer Res. 2012;32(2):445–452.
12. Shi Y, Chen L, Li J, et al. Prognostic and predictive values of pERK1/2 
and pAkt-1 expression in non-small cell lung cancer patients treated 
with adjuvant chemotherapy. Tumour Biol. 2011;32(2):381–390.
13. Carden CP, Stewart A, Thavasu P, et al. The association of PI3 kinase 
signaling and chemoresistance in advanced ovarian cancer. Mol Cancer 
Ther. 2012;11(7):1609–1617.
14. Cancer Genome Atlas Network. Comprehensive molecular portraits of 
human breast tumours. Nature. 2012;490(7418):61–70.
15. Cardoso F, Costa A, Senkus E, et al. 3rd ESO-ESMO International 
Consensus Guidelines for Advanced Breast Cancer (ABC 3). Ann Oncol. 
2017;28(Suppl 12).
16. Perou CM, Sorlie T, Eisen MB, et al. Molecular portraits of human 
breast tumours. Nature. 2000;406(6797):747–752.
17. Miller TW, Hennessy BT, Gonzalez-Angulo AM, et al. Hyperactivation 
of phosphatidylinositol-3 kinase promotes escape from hormone 
dependence in estrogen receptor-positive human breast cancer. J Clin 
Invest. 2010;120(7):2406–2413.
18. Bosch A, Li Z, Bergamaschi A, et al. PI3K inhibition results in enhanced 
estrogen receptor function and dependence in hormone receptor-positive 
breast cancer. Sci Transl Med. 2015;7(283):283ra51.
19. Sanchez CG, Ma CX, Crowder RJ, et al. Preclinical modeling of 
combined phosphatidylinositol-3-kinase inhibition with endocrine 
therapy for estrogen receptor-positive breast cancer. Breast Cancer 
Res. 2011;13(2):R21.
20. Garrett JT, Arteaga CL. Resistance to HER2-directed antibodies and 
tyrosine kinase inhibitors: mechanisms and clinical implications. Cancer 
Biol Ther. 2011;11(9):793–800.
21. Berns K, Horlings HM, Hennessy BT, et al. A functional genetic approach 
identifies the PI3K pathway as a major determinant of trastuzumab 
resistance in breast cancer. Cancer Cell. 2007;12(4):395–402.
22. Chandarlapaty S, Sakr RA, Giri D, et al. Frequent mutational activation 
of the PI3K-AKT pathway in trastuzumab-resistant breast cancer. Clin 
Cancer Res. 2012;18(24):6784–6791.
23. Esteva FJ, Guo H, Zhang S, et al. PTEN, PIK3CA, p-AKT, and 
p-p70S6K status: association with trastuzumab response and survival 
in patients with HER2-positive metastatic breast cancer. Am J Pathol. 
2010;177(4):1647–1656.
24. Baselga J, Campone M, Piccart M, et al. Everolimus in postmenopausal 
hormone-receptor-positive advanced breast cancer. N Engl J Med. 
2012;366:520–529.
25. Hortobagyi GN, Chen D, Piccart M, et al. Correlative analysis of genetic 
alterations and everolimus benefit in hormone receptor-positive, human 
epidermal growth factor receptor 2-negative advanced breast cancer: 
results from BOLERO-2. J Clin Oncol. 2016;34(5):419–426.
26. Jordan NJ, Dutkowski CM, Barrow D, et al. Impact of dual mTORC1/2 
mTOR kinase inhibitor AZD8055 on acquired endocrine resistance in 
breast cancer in vitro. Breast Cancer Res. 2014;16(1):R12.
27. Wolff AC, Lazar AA, Bondarenko I, et al. Randomized Phase III 
placebo-controlled trial of letrozole plus oral temsirolimus as first-line 
endocrine therapy in postmenopausal women with locally advanced or 
metastatic breast cancer. J Clin Oncol. 2013;31(2):195–202.
28. Krop IE, Mayer IA, Ganju V, et al. Pictilisib for oestrogen receptor-
positive, aromatase inhibitor-resistant, advanced or metastatic breast 
cancer (FERGI): a randomised, double-blind, placebo-controlled, phase 
2 trial. Lancet Oncol. 2016;17(6):811–821.
29. Maira SM, Pecchi S, Huang A, et al. Identification and characterization 
of NVP-BKM120, an orally available pan-class I PI3-kinase inhibitor. 
Mol Cancer Ther. 2012;11(2):317–328.
30. Brachmann SM, Kleylein-Sohn J, Gaulis S, et al. Characterization of the 
mechanism of action of the pan class I PI3K inhibitor NVP-BKM120 
across a broad range of concentrations. Mol Cancer Ther. 2012;11(8): 
1747–1757.
31. Rodon J, Brana I, Siu LL, et al. Phase I dose-escalation and-
expansion study of buparlisib (BKM120), an oral pan-Class I PI3K 
inhibitor, in patients with advanced solid tumors. Invest New Drugs. 
2014;32(4):670–681.
32. LoPiccolo J, Blumenthal GM, Bernstein WB, Dennis PA. Targeting 
the PI3K/Akt/mTOR pathway: effective combinations and clinical 
considerations. Drug Resist Updat. 2008;11(1–2):32–50.
33. West KA, Castillo SS, Dennis PA. Activation of the PI3K/Akt 
pathway and chemotherapeutic resistance. Drug Resist Updat. 
2002;5(6):234–248.
34. Massacesi C, Di Tomaso E, Urban P, et al. PI3K inhibitors as new cancer 
therapeutics: implications for clinical trial design. Onco Targets Ther. 
2016;9:203–210.
35. Burris HA 3rd. Overcoming acquired resistance to anticancer 
therapy: focus on the PI3K/AKT/mTOR pathway. Cancer Chemother 
Pharmacol. 2013;71(4):829–842.
36. Mayer IA, Abramson VG, Isakoff SJ, et al. Stand up to cancer phase 
Ib study of pan-phosphoinositide-3-kinase inhibitor buparlisib with 
letrozole in estrogen receptor-positive/human epidermal growth 
factor receptor 2-negative metastatic breast cancer. J Clin Oncol. 
2014;32(12):1202–1209.
37. Baselga J, Im SA, Iwata H, et al. Buparlisib plus fulvestrant versus 
placebo plus fulvestrant in postmenopausal, hormone receptor-positive, 
HER2-negative, advanced breast cancer (BELLE-2): a randomised, dou-
ble-blind, placebo-controlled, phase 3 trial. Lancet Oncol. 2017;18(7): 
904–916.
38. Martin M, Chan A, Dirix L, et al. A randomized adaptive phase II/
III study of buparlisib, a pan-class I PI3K inhibitor, combined with 
paclitaxel for the treatment of HER2-advanced breast cancer (BELLE-4). 
Ann Oncol. 2017;28(2):313–320.
39. Miller TW, Rexer BN, Garrett JT, Arteaga CL. Mutations in the 
phosphatidylinositol 3-kinase pathway: role in tumor progression 
and therapeutic implications in breast cancer. Breast Cancer Res. 
2011;13(6):224.
40. Hurvitz SA, Andre F, Jiang Z, et al. Combination of everolimus with 
trastuzumab plus paclitaxel as first-line treatment for patients with 
HER2-positive advanced breast cancer (BOLERO-1): a phase 3, ran-
domised, double-blind, multicentre trial. Lancet Oncol. 2015;16(7): 
816–829.
41. Andre F, O’Regan R, Ozguroglu M, et al. Everolimus for women 
with trastuzumab-resistant, HER2-positive, advanced breast cancer 
(BOLERO-3): a randomised, double-blind, placebo-controlled phase 
3 trial. Lancet Oncol. 2014;15(6):580–591.
42. Andre F, Hurvitz S, Fasolo A, et al. Molecular Alterations and 
everolimus efficacy in human epidermal growth factor receptor 
2-overexpressing metastatic breast cancers: combined exploratory 
biomarker analysis from BOLERO-1 and BOLERO-3. J Clin Oncol. 
2016;34(18):2115–2124.
43. Swain SM, Kim SB, Cortes J, et al. Pertuzumab, trastuzumab, and 
docetaxel for HER2-positive metastatic breast cancer (CLEOPATRA 
study): overall survival results from a randomised, double-blind, 
placebo-controlled, phase 3 study. Lancet Oncol. 2013;14(6): 
461–471.
Breast Cancer - Targets and Therapy 2018:10 submit your manuscript | www.dovepress.com
Dovepress 
Dovepress
Breast Cancer - Targets and Therapy
Publish your work in this journal
Submit your manuscript here: https://www.dovepress.com/breast-cancer---targets-and-therapy-journal 
Breast Cancer - Targets and Therapy is an international, peer- 
reviewed open access journal focusing on breast cancer research, 
identification of therapeutic targets and the optimal use of preven-
tative and integrated treatment interventions to achieve improved 
 outcomes, enhanced survival and quality of life for the cancer patient. 
The manuscript management system is completely online and includes 
a very quick and fair peer-review system, which is all easy to use. Visit 
http://www.dovepress.com/testimonials.php to read real quotes from 
published authors.
Dovepress
29
Buparlisib in breast cancer
44. Baselga J, Cortes J, Im SA, et al. Biomarker analyses in CLEOPATRA: 
a phase III, placebo-controlled study of pertuzumab in human epidermal 
growth factor receptor 2-positive, first-line metastatic breast cancer. 
J Clin Oncol. 2014;32(33):3753–3761.
45. Saura C, Bendell J, Jerusalem G, et al. Phase Ib study of buparlisib plus 
trastuzumab in patients with HER2-positive advanced or metastatic 
breast cancer that has progressed on Trastuzumab-based therapy. Clin 
Cancer Res. 2014;20(7):1935–1945.
46. Loibl S, de la Pena L, Nekljudova V, et al. Neoadjuvant buparlisib plus 
trastuzumab and paclitaxel for women with HER2+ primary breast 
cancer: a randomised, double-blind, placebo-controlled phase II trial 
(NeoPHOEBE). Eur J Cancer. 2017;85:133–145.
47. Guerin M, Rezai K, Isambert N, et al. PIKHER2: A phase IB study 
evaluating buparlisib in combination with lapatinib in trastuzumab-
resistant HER2-positive advanced breast cancer. Eur J Cancer. 
2017;86:28–36.
